No Data
No Data
Hoth Therapeutics' Expansion and AI Integration Bolster Buy Rating
H.C. Wainwright Maintains Hoth Therapeutics(HOTH.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright analyst Ram Selvaraju maintains $Hoth Therapeutics(HOTH.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 41.2%
Express News | Hoth Therapeutics Approved To Proceed With First-In-Human Phase 2a Clinical Trial Of HT-001 For Treatment Of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
Express News | Hoth Therapeutics Expands Clinical Trial for Cancer Patients
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersHoldco Nuvo Group DG (NASDAQ:NUVO) shares increased by 21.5% to $1.92 during Wednesday's after-market session. The company's market cap stands at $63.8 million. Entero Therapeutics (NASDAQ:ENTO
Why Calavo Growers Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Calavo Growers, Inc. (NASDAQ:CVGW) rose sharply in today's pre-market trading after the company reported second-quarter financial results.Total net sales surged 16.5% year-over-year to $184.
No Data